Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIMOVIP: IP vs IV Chemotherapy in Advanced Ovarian Cancer
NCT03025477Phase 2Recruiting
- Sponsor
- Groupe Hospitalier Diaconesses Croix Saint-Simon
- Start
- Oct 2016
- Primary completion
- Oct 2021
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132), epirubicin in Epithelial Ovarian Cancer (EOC), sponsored by Groupe Hospitalier Diaconesses Croix Saint-Simon. Started Oct 2016; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)epirubicin
03
Conditions
Epithelial Ovarian Cancer (EOC)
Beyond the preview
Go deeper on NCT03025477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03025477.